The Power of PoP

POP BIO uses two patented porphyrin-phospholipid (PoP) liposome technologies to create nanomedicines to address needs in oncology and infectious disease

1.) The Spontaneous Nanoliposome Antigen Particleization (SNAP) platform enables the rapid development of highly immunogenic vaccines

2.) Chemophototherapy (CPT) using PoP liposomes to deliver targeted concentrations of chemotherapy drugs to tumors expose to specific laser light.

Learn more about our technologies

Latest News

September 13, 2024

POP BIO announces findings for an Alzheimer’s Disease polyvalent peptide immunotherapy

POP BIO announces findings for an Alzheimer’s Disease polyvalent peptide immunotherapy
August 21, 2024

POP BIO and FunPep Announce Collaboration for Antibody-Inducing Peptide Therapy

POP Biotechnologies announces the furtherance of research with FunPep. Advanced preclinical testing of antibody-inducing peptides will be carried out.
August 14, 2024

POP BIO and EuBiologics’ Shingles Vaccine Enters Phase 1 Clinical Trials

POP Biotechnologies announces the commencement of dosing of the shingles vaccine “EuHZV” in collaboration with EuBiologics in a Phase 1 clinical study in Korea